【24h】

Processing thermally labile drugs by hot-melt extrusion: The lesson with gliclazide

机译:通过热熔挤压加工热不稳定药物:Gliclazide的课程

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Graphical abstract Display Omitted Abstract The formation of molecularly dispersed amorphous solid dispersions by the hot-melt extrusion technique relies on the thermal and mechanical energy inputs, which can cause chemical degradation of drugs and polymeric carriers. Additionally, drug degradation may be exacerbated as drugs convert from a more stable crystalline form to a higher energy amorphous form. Therefore, it is imperative to study how drug degrades and evaluate methods to minimize drug degradation during the extrusion process. In this work, gliclazide was used as a model thermally labile drug for the degradation kinetics and process optimization studies. Preformulation studies were conducted using thermal analyses, and liquid chromatography–mass spectroscopy to identify drug degradation pathways and to determine initial extrusion conditions. Formulations containing 10% drug and 90% AFFINISOL? HPMC HME 100LV were then extruded using a twin screw extruder, and the extrudates were characterized using X-ray powder diffraction, modulated dynamic scanning calorimetry, and potency testing to evaluate physicochemical properties. The energies of activation for both amorphous gliclazide, crystalline gliclazide, and gliclazide solution were calculated using the Arrhenius equation to further guide the extrusion optimization process. Preformulation studies identify two hydrolysis degradation pathways of gliclazide at elevated temperatures. The activation energy study indicates a significantly higher degradation rate for the amorphous gliclazide compared to the crystalline form. After optimization of the hot-melt extrusion process, including improved screw designs, machine setup, and processing conditions, gliclazide amorphous solid dispersion with ~95% drug recovery was achieved. The ability to process thermally labile drugs and polymers using hot-melt extrusion will significantly expand the possible applications of this manufacturing process. ]]>
机译:图形摘要显示省略了通过热熔挤出技术的分子分散的无定形固体分散体的形成依赖于热和机械能量输入,这可能导致药物和聚合物载体的化学降解。另外,药物降解可能加剧,因为药物从更稳定的结晶形式转化为更高的能量无定形形式。因此,研究药物如何降解和评估挤出过程中药物降解最小化的方法是迫切的。在这项工作中,Gliclazide被用作用于降解动力学和过程优化研究的模型热不稳定药物。使用热分析和液相色谱 - 质谱进行预先形成研究,以鉴定药物降解途径并确定初始挤出条件。含有10%药物和90%阿元醇的制剂?然后使用双螺杆挤出机挤出HPMC HME 100LV,并使用X射线粉末衍射,调制动态扫描量热法和效力测试表征挤出物,以评估物理化学特性。使用Arrenius方程计算无定形神经甲醇,结晶神经脂醇和Gliclazide溶液的活化的能量,以进一步引导挤出优化过程。预制研究在升高的温度下鉴定了Gliclazide的两个水解降解途径。激活能量研究表明与结晶形式相比,无定形神经甲醇的降解速率显着更高。优化热熔挤出工艺后,包括改进的螺钉设计,机器设置和加工条件,达到了〜95%药物回收的Gliclazide无定形固体分散体。使用热熔挤出处理热不稳定药物和聚合物的能力将显着扩展该制造过程的可能应用。 ]]>

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号